View Older Stories
-
Wells Fargo Downgrades Phreesia Inc. (PHR) to Equal Weight
-
Phreesia eliminates 220 positions in restructuring plan
-
Phreesia Inc. (PHR) PT Lowered to $16 at Raymond James
-
Citizens Downgrades Phreesia Inc. (PHR) to Market Perform
-
Phreesia Inc. (PHR) PT Lowered to $14 at BMO Capital Amid Net Solutions Headwind
-
KeyBanc Reiterates Overweight Rating on Phreesia Inc. (PHR)
-
Phreesia Inc. (PHR) PT Lowered to $14 at DA Davidson on Lowered Guidance
-
Phreesia Inc. (PHR) PT Lowered to $23 at Piper Sandler
-
Phreesia Inc. (PHR) PT Lowered to $20 at Stephens
-
Phreesia Inc. (PHR) PT Lowered to $22 at Canaccord
-
Phreesia Inc. (PHR) PT Lowered to $14 at Needham, 'Buyers at these depressed levels'
-
Phreesia Inc. (PHR) PT Lowered to $19 at RBC Capital
-
Phreesia sinks 26% after substantial outlook cut; Wall Street downgrades shares
-
RBC Cautious on Phreesia Inc. (PHR): 'we will be listening for further color on any potential for improved visibility into pharma marketing spending'
-
JPMorgan Downgrades Phreesia Inc. (PHR) to Neutral
-
Truist Securities Downgrades Phreesia Inc. (PHR) to Hold
-
Baird Downgrades Phreesia Inc. (PHR) to Neutral
-
Phreesia Inc. (PHR) Misses Q4 EPS by 4c, Beats on Revenue; Offers Guidance
-
Phreesia Inc. (PHR) PT Lowered to $19 at Mizuho
-
Phreesia launches ProviderConnect for healthcare provider marketing
-
Phreesia Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
-
Which healthcare stocks are at risk from AI and which to buy
-
Phreesia Inc. (PHR) PT Lowered to $30 at DA Davidson
-
Wells Fargo Starts Phreesia Inc. (PHR) at Overweight
-
Piper Sandler: 'We Would be Buyers of DOCS and PHR Following Pharma Marketing KOL Lunch'
-
Piper: 'We Would be Buyers of DOCS and PHR Following Pharma Marketing KOL Lunch in Boston'
-
Phreesia Inc. (PHR) PT Lowered to $25 at Raymond James
-
Phreesia Inc. (PHR) PT Lowered to $28 at Mizuho
-
Phreesia (PHR) Delivered Better than Expected F3Q26 Results - DA Davidson
-
Phreesia Inc. (PHR) PT Lowered to $33 at Canaccord Genuity
-
Phreesia (PHR) Has a Strong Market Position, is a Leading Brand - Citizens
-
Phreesia Inc. (PHR) Tops Q3 EPS by 7c, Beats on Revenue; Offers FY26 Revenue Guidance
-
Phreesia Inc. (PHR) PT Raised to $35 at DA Davidson
-
Phreesia Inc. (PHR) PT Raised to $36 at Truist Securities
-
Phreesia Inc. (PHR) PT Raised to $34 at Citizens JMP
-
Truist Securities Reiterates Sell Rating on Phreesia Inc. (PHR)
-
Phreesia Inc. (PHR) PT Raised to $33 at Raymond James
-
DA Davidson Assumes Phreesia Inc. (PHR) at Buy
-
Phreesia Inc. (PHR) PT Raised to $38 at Canaccord Genuity
-
Phreesia Inc. (PHR) PT Raised to $35 at Needham
-
Phreesia Inc. (PHR) Tops Q2 EPS by 7c, provides guidance
-
Phreesia launches VoiceAI to handle patient calls with conversational AI
-
Mizuho Starts Phreesia Inc. (PHR) at Outperform
-
KeyBanc on Phreesia Inc. (PHR): 'See Multiple Growth Catalysts for GARP-y'
-
Phreesia partners with Sesame Workshop for 5-year pediatric health initiative
-
JPMorgan Reiterates Overweight Rating on Phreesia Inc. (PHR)
-
DA Davidson Reiterates Buy Rating on Phreesia Inc. (PHR)
-
Phreesia Inc. (PHR) PT Lowered to $34 at Canaccord Genuity
-
Raymond James Reiterates Outperform Rating on Phreesia Inc. (PHR)
-
Piper Sandler Reiterates Overweight Rating on Phreesia Inc. (PHR) Following EPS

